Vandana Singh

Syndax Pharmaceuticals halts axatilimab in idiopathic pulmonary fibrosis after the candidate misses the primary endpoint in a Phase 2 trial.

FDA approves Teva's Weltruza, a once-monthly injectable for adults with schizophrenia, eliminating the need for daily oral medication.

Quantum BioPharma signed an agreement with Thermo Fisher to initiate a Phase 2 clinical trial for its multiple sclerosis therapy, Lucid-MS.

HeartBeam Secures FDA Designation for At-Home Heart Attack Detection System

Regeneron reports positive trial data for ubamatamab in ovarian cancer and trevogrumab for muscle preservation during weight loss.

Monte Rosa Therapeutics reports positive Phase 1 trial data for MRT-8102 and outlines upcoming Phase 2 studies in inflammatory diseases.

Eli Lilly says Phase 3 Foundayo (Orforglipron) data show reduced cardiovascular and type 2 diabetes risks in adults with obesity.

Nexalin Technology (NXL) stock surged 80% on massive volume following a 10-year South American distribution and manufacturing deal.

Vanda's Phase 3 trial of HETLIOZ for DSWPD met its primary endpoint, advancing sleep onset by 42.5 minutes. sNDA submission planned.

FDA approves AbbVie's Juvmo for Parkinson's disease, the first D1/D5 agonist. U.S. launch set for Oct 2026. Get pricing and sales data.